DK0480525T3 - Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve - Google Patents

Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve

Info

Publication number
DK0480525T3
DK0480525T3 DK91202615T DK91202615T DK0480525T3 DK 0480525 T3 DK0480525 T3 DK 0480525T3 DK 91202615 T DK91202615 T DK 91202615T DK 91202615 T DK91202615 T DK 91202615T DK 0480525 T3 DK0480525 T3 DK 0480525T3
Authority
DK
Denmark
Prior art keywords
surface antigen
hep
virus
recombinant hepatitis
obtaining recombinant
Prior art date
Application number
DK91202615T
Other languages
English (en)
Inventor
Gonzalez Verena Lucila Mucio
Arias Eduardo Penton
Garcia Manuel Palou
Escobar Giuvel Fontirrochi
Galvez Marcelo Nazabal
Griego Marta De Jesus Gonzalez
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Jul Pardron
Albajes Victoria Ramirez
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Martinez Luis Saturnin Herrera
Cano Carlos Antonio Duarte
Suarez Lilia Luisa Perez
Caballero Jose Garcia
La Riva De La Riva Gustavo De
Lasa Alexis S Musacchio
Suarez Jose Garcia
Avila Ramon Alexis Santiago
Original Assignee
Cigb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cigb filed Critical Cigb
Application granted granted Critical
Publication of DK0480525T3 publication Critical patent/DK0480525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK91202615T 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve DK0480525T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal

Publications (1)

Publication Number Publication Date
DK0480525T3 true DK0480525T3 (da) 1999-08-30

Family

ID=5459466

Family Applications (2)

Application Number Title Priority Date Filing Date
DK91202615T DK0480525T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve
DK98202021T DK0864649T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98202021T DK0864649T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat

Country Status (9)

Country Link
EP (2) EP0864649B1 (da)
JP (2) JP3189212B2 (da)
AT (2) ATE175445T1 (da)
AU (1) AU649482B2 (da)
CU (1) CU22290A1 (da)
DE (2) DE69130724T2 (da)
DK (2) DK0480525T3 (da)
ES (2) ES2129025T3 (da)
GR (1) GR3029582T3 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960001122A (ko) * 1994-06-09 1996-01-25 엠. 리몬타 비달 재조합 단일사슬 Fv 항체 절편과 B형 간염 바이러스 표면 항원의 면역정제를 위한 그 용도
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (en) * 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
RU2230782C1 (ru) * 2003-03-14 2004-06-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Трансформированный штамм дрожжей pichia angusta - продуцент рекомбинантного поверхностного антигена вируса гепатита в - hbsag/ayw
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
EA201892212A1 (ru) 2016-03-31 2019-03-29 Сентро Де Инхеньерия Хенетика И Биотекнолохия Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
EP0280470B1 (en) * 1987-02-27 1993-07-07 Merck & Co. Inc. Method of purifying recombinant pres-1/s-2/s hepatitis b antigen from yeast
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
EP0864649A2 (en) 1998-09-16
JP2001231582A (ja) 2001-08-28
ES2264183T3 (es) 2006-12-16
DE69130724D1 (de) 1999-02-18
GR3029582T3 (en) 1999-06-30
EP0864649B1 (en) 2006-04-26
DE69133525T2 (de) 2006-11-23
DE69130724T2 (de) 1999-06-17
JP3242640B2 (ja) 2001-12-25
DE69133525D1 (de) 2006-06-01
DK0864649T3 (da) 2006-08-28
DE69133525T8 (de) 2007-03-08
AU8557491A (en) 1992-04-30
JPH0576370A (ja) 1993-03-30
ES2129025T3 (es) 1999-06-01
EP0864649A3 (en) 1998-11-11
ATE175445T1 (de) 1999-01-15
EP0480525A2 (en) 1992-04-15
EP0480525B1 (en) 1999-01-07
AU649482B2 (en) 1994-05-26
EP0480525A3 (en) 1992-09-30
ATE324451T1 (de) 2006-05-15
CU22290A1 (es) 1995-01-31
JP3189212B2 (ja) 2001-07-16

Similar Documents

Publication Publication Date Title
EP0271302A3 (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
ATE159031T1 (de) Antigene sowie verfahren zu deren herstellung
IE873314L (en) T cell epitopes of the hepatitis b virus nucleocapsid¹protein
DK0864649T3 (da) Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat
EP0330359A3 (en) Composition useful in the diagnosis and treating of hiv-1 infection
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
DK0791064T3 (da) Fremgangsmåde til forögelse af immunogeniciteten af en immunogen forbindelse eller et hapten og anvendelse heraf til fremstilling af vacciner
AU4233585A (en) Vaccine against rabies and preparation process thereof
EP0250253A3 (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
DK0425082T3 (da) Vacciner
MA22938A1 (fr) Procede d'obtention d'un vaccin antirabique avirulent.
HK126095A (en) Hepatitis a virus vaccines
DK312687D0 (da) Varicella-zoster virus (vzv), fremgangsmaade til fremstilling deraf og vaccine indeholdende vzv
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
DK645687D0 (da) Fremgangsmaade til fremstilling af en vaccine mod hepatitis b og den opnaaede vaccine
EP0293201A3 (en) Method of vaccination for hepatitis b virus
ATE137505T1 (de) Schützende antikörper erregende plasmodium falciparum antigene und deren verwendung in impfstoffen
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
Dardanoni et al. Vaccination against hepatitis B: Evaluation of the prevaccination markers.
Migneco et al. Vaccination against hepatitis B of subjects from a hospital staff.
Spier Monoclonal antibodies and functional cell lines: progress and applications: Eds Roger H. Kennett, Kathleen B. Bechtol & Thomas J. McKearn Publishers Plenum Press, New York & London 426pp 1984 $49.50
DK123288A (da) Fremgangsmaade til remsning af rekombinant hepatitis b overfladeantigen
DK0419446T3 (da) Kompleks, som er egnet til gennemførelse af en fremgangsmåde til rensning af præ-S-hepatitis-B-virus-overfladeantigen

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment